# QLS1410 in Participants With Uncontrolled Hypertension

Study · id `cardio:ct-nct07489612` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07489612](<https://clinicaltrials.gov/study/NCT07489612>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07489612

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 260 participants.

## Technical summary

Registry record NCT07489612. Randomized; quadruple masking; primary purpose treatment. Start 2026-04 (anticipated); primary completion 2026-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 260 participants (planned count; ClinicalTrials.gov record NCT07489612, source copy `cardio:ctgov-nct07489612-2026-05-22`, retrieved 2026-10-26)
- Planned start: 2026-04 (anticipated) (ClinicalTrials.gov record NCT07489612, source copy `cardio:ctgov-nct07489612-2026-05-22`, retrieved 2026-10-26)
- Primary completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT07489612, source copy `cardio:ctgov-nct07489612-2026-05-22`, retrieved 2026-10-26)
- Completion: 2027-03 (anticipated) (ClinicalTrials.gov record NCT07489612, source copy `cardio:ctgov-nct07489612-2026-05-22`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07489612, source copy `cardio:ctgov-nct07489612-2026-05-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ENROLLING\_BY\_INVITATION" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07489612-2026-05-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: QLS1410 in Participants With Uncontrolled Hypertension
- Condition: Hypertension (HTN)
- Intervention (Drug): Dose 1 of QLS1410
- Intervention (Drug): Dose 2 of QLS1410
- Intervention (Drug): Dose 3 of QLS1410
- Intervention (Drug): placebo
- Lead sponsor: Qilu Pharmaceutical Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Qilu Pharmaceutical Co., Ltd. (`cardio:org-qilu-pharmaceutical-co-ltd`)

## Provenance

Content hash: ce20064385d4b8947e381d5d4368b6401f61a3ee1f8eb3f973f154cadab25b18
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
